1. Home
  2. PCRX vs EVV Comparison

PCRX vs EVV Comparison

Compare PCRX & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • EVV
  • Stock Information
  • Founded
  • PCRX 2006
  • EVV 2003
  • Country
  • PCRX United States
  • EVV United States
  • Employees
  • PCRX N/A
  • EVV N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • EVV Finance/Investors Services
  • Sector
  • PCRX Health Care
  • EVV Finance
  • Exchange
  • PCRX Nasdaq
  • EVV Nasdaq
  • Market Cap
  • PCRX 1.2B
  • EVV 1.2B
  • IPO Year
  • PCRX 2011
  • EVV N/A
  • Fundamental
  • Price
  • PCRX $22.76
  • EVV $9.93
  • Analyst Decision
  • PCRX Buy
  • EVV
  • Analyst Count
  • PCRX 5
  • EVV 0
  • Target Price
  • PCRX $32.40
  • EVV N/A
  • AVG Volume (30 Days)
  • PCRX 479.4K
  • EVV 323.7K
  • Earning Date
  • PCRX 11-05-2025
  • EVV 01-01-0001
  • Dividend Yield
  • PCRX N/A
  • EVV 9.66%
  • EPS Growth
  • PCRX N/A
  • EVV N/A
  • EPS
  • PCRX N/A
  • EVV N/A
  • Revenue
  • PCRX $705,848,000.00
  • EVV N/A
  • Revenue This Year
  • PCRX $7.36
  • EVV N/A
  • Revenue Next Year
  • PCRX $10.07
  • EVV N/A
  • P/E Ratio
  • PCRX N/A
  • EVV N/A
  • Revenue Growth
  • PCRX 2.25
  • EVV N/A
  • 52 Week Low
  • PCRX $16.00
  • EVV $8.52
  • 52 Week High
  • PCRX $27.64
  • EVV $10.07
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.28
  • EVV 34.25
  • Support Level
  • PCRX $24.31
  • EVV $9.99
  • Resistance Level
  • PCRX $26.05
  • EVV $10.23
  • Average True Range (ATR)
  • PCRX 0.82
  • EVV 0.10
  • MACD
  • PCRX -0.20
  • EVV -0.02
  • Stochastic Oscillator
  • PCRX 18.36
  • EVV 4.41

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest

Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.

Share on Social Networks: